The non-surgical treatment of adult patients with short bowel syndrome

Expert Opinion on Orphan Drugs

Volumn 1, Issue 7, 2013, Pages 527-538

  Jeppesen, Palle Bekker ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Home parenteral nutrition; Intestinal failure; Intestinal insufficiency; Short bowel syndrome; Treatment

Indexed keywords

ANTIDIARRHEAL AGENT; BILE ACID; CREATININE; HISTAMINE H2 RECEPTOR AGONIST; HORMONE; PROTON PUMP INHIBITOR;

ABSORPTION; BEVERAGE; BODY COMPOSITION; BODY WEIGHT; CONSERVATIVE TREATMENT; CREATININE URINE LEVEL; DIET; DIET THERAPY; DIGESTION; ENDOCRINE CELL; ENERGY ABSORPTION; ENTERIC FEEDING; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; GASTROINTESTINAL TRACT; HORMONAL THERAPY; HUMAN; INTESTINE BLOOD FLOW; INTESTINE FUNCTION; INTESTINE INNERVATION; INTESTINE RESECTION; MUCOSAL DISEASE; NERVE ENDING; ORAL REHYDRATION THERAPY; PATHOPHYSIOLOGY; REVIEW; SHORT BOWEL SYNDROME;

EID: 84896691590     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.814536     Document Type: Review

References (76)

1. Joly F, Dray X, Corcos O, et al. Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterology 2009;136:824-31
2. Newton CR. Effect of codeine phosphate, Lomotil, and Isogel on ileostomy function. Gut 1978;19:377-83
3. King RF, Norton T, Hill GL. A double-blind crossover study of the effect of loperamide hydrochloride and codeine phosphate on ileostomy output. Aust NZ J Surg 1982;52:121-4
4. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001;120:806-15
5. Nightingale JM, Walker ER, Farthing MJ, Lennard Jones JE. Effect of omeprazole on intestinal output in the short bowel syndrome. Aliment Pharmacol Ther 1991;5:405-12
6. Jeppesen PB, Staun M, Tjellesen L, Mortensen PB. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut 1998;43:763-9
7. Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep 2007;9:463-7
8. Jeppesen PB. The use of hormonal growth factors in the treatment of patients with short-bowel syndrome. Drugs 2006;66:581-9
9. Nightingale JM, Kamm MA, van der Sijp JR, et al. Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the colonic brake to gastric emptying. Gut 1996;39:267-72
10. Jeppesen PB, Hartmann B, Hansen BS, et al. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999;45:559-63
11. McIntyre PB, Fitchew M, Lennard Jones JE. Patients with a high jejunostomy do not need a special diet. Gastroenterology 1986;91:25-33
12. Levy E, Frileux P, Sandrucci S, et al. Continuous enteral nutrition during the early adaptive stage of the short bowel syndrome. Br J Surg 1988;75:549-53
13. Cosnes J, Evard D, Beaugerie L, et al. Improvement in protein absorption with a small-peptide-based diet in patients with high jejunostomy. Nutrition 1992;8:406-11
14. Lai HS, Chen WJ, Chen KM, Lee YN. Effects of monomeric and polymeric diets on small intestine following massive resection. Taiwan Yi Xue Hui Za Zhi 1989;88:982-8
15. Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel [see comments]. Lancet 1994;343:373-6
16. Nordgaard I, Hansen BS, Mortensen PB. Importance of colonic support for energy absorption as small- bowel failure proceeds. Am J Clin Nutr 1996;64:222-31
17. Jeppesen PB, Christensen MS, Hoy CE, Mortensen PB. Essential fatty acid deficiency in patients with severe fat malabsorption. Am J Clin Nutr 1997;65:837-43
18. Jeppesen PB, Hoy CE, Mortensen PB. Deficiencies of essential fatty acids, vitamin A and E and changes in plasma lipoproteins in patients with reduced fat absorption or intestinal failure. Eur J Clin Nutr 2000;54:632-42
19. Hessov I, Andersson H, Isaksson B. Effects of a low-fat diet on mineral absorption in small-bowel disease. Scand J Gastroenterol 1983;18:551-4
20. Ovesen L, Chu R, Howard L. The influence of dietary fat on jejunostomy output in patients with severe short bowel syndrome. Am J Clin Nutr 1983;38:270-7
21. Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. Gut 1998;43:478-83
22. Atia A, Girard-Pipau F, Hebuterne X, et al. Macronutrient absorption characteristics in humans with short bowel syndrome and jejunocolonic anastomosis: starch is the most important carbohydrate substrate, although pectin supplementation may modestly enhance short chain fatty acid production and fluid absorption. JPEN J Parenter Enteral Nutr 2011;35:229-40
23. Qvitzau S, Matzen P, Madsen P. Treatment of chronic diarrhoea: loperamide versus ispaghula husk and calcium. Scand J Gastroenterol 1988;23:1237-40
24. Lund P, Sangild PT, Aunsholt L, et al. Randomised controlled trial of colostrum to improve intestinal function in patients with short bowel syndrome. Eur J Clin Nutr 2012;66:1059-65
25. Arrigoni E, Marteau P, Briet F, et al. Tolerance and absorption of lactose from milk and yogurt during short-bowel syndrome in humans. Am J Clin Nutr 1994;60:926-9
26. Scolapio JS, McGreevy K, Tennyson GS, Burnett OL. Effect of glutamine in short-bowel syndrome. Clin Nutr 2001;20:319-23
27. Woolf GM, Miller C, Kurian R, Jeejeebhoy KN. Nutritional absorption in short bowel syndrome. Evaluation of fluid, calorie, and divalent cation requirements. Dig Dis Sci 1987;32:8-15
28. Newton CR, Drury P, Gonvers JJ, et al. Incidence and treatment of sodium depletion in ileostomists. Scand J Gastroenterol Suppl 1982;74:159-60
29. Griffin GE, Fagan EF, Hodgson HJ, Chadwick VS. Enteral therapy in the management of massive gut resection complicated by chronic fluid and electrolyte depletion. Dig Dis Sci 1982;27:902-8
30. Kennedy HJ, Al Dujaili EA, Edwards CR, Truelove SC. Water and electrolyte balance in subjects with a permanent ileostomy. Gut 1983;24:702-5
31. Newton CR, Gonvers JJ, McIntyre PB, et al. Effect of different drinks on fluid and electrolyte losses from a jejunostomy. J R Soc Med 1985;78:27-34
32. Rodrigues CA, Lennard Jones JE, Thompson DG, Farthing MJ. What is the ideal sodium concentration of oral rehydration solutions for short bowel patients? [abstract]. Clin Sci 1988;74:69
33. Nightingale JM, Lennard Jones JE, Walker ER, Farthing MJ. Oral salt supplements to compensate for jejunostomy losses: comparison of sodium chloride capsules, glucose electrolyte solution, and glucose polymer electrolyte solution. Gut 1992;33:759-61
34. Williams NS, Evans P, King RF. Gastric acid secretion and gastrin production in the short bowel syndrome. Gut 1985;26:914-19
35. Heizer WD, Cleveland CR, Iber FL. Gastric inactivation of pancreatic supplements. Bull Johns Hopkins Hosp 1965;116:261-5
36. Go VL, Poley JR, Hofmann AF, Summerskill WH. Disturbances in fat digestion induced by acidic jejunal pH due to gastric hypersecretion in man. Gastroenterology 1970;58:638-46
37. Houben GM, Hooi J, Hameeteman W, Stockbrugger RW. Twenty-four-hour intragastric acidity: 300 mg ranitidine b. d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo. Aliment Pharmacol Ther 1995;9:649-54
38. Jacobsen O, Ladefoged K, Stage JG, Jarnum S. Effects of cimetidine on jejunostomy effluents in patients with severe short-bowel syndrome. Scand J Gastroenterol 1986;21:824-8
39. Williams NS, Cooper JC, Axon AT, et al. Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea. Br Med J Clin Res Ed 1984;289:1027-8
40. Cooper JC, Williams NS, King RF, Barker MC. Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea. Br J Surg 1986;73:128-31
41. Ladefoged K, Christensen KC, Hegnhoj J, Jarnum S. Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome [see comments]. Gut 1989;30:943-9
42. OKeefe SJD, Peterson ME, Fleming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN J Parenter Enteral Nutr 1994;18:26-34
43. OKeefe SJ, Haymond MW, Bennet WM, et al. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies. Gastroenterology 1994;107:379-88
44. Nehra V, Camilleri M, Burton D, et al. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol 2001;96:1494-8
45. Buchman AL, Fryer J, Wallin A, et al. Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study. JPEN J Parenter Enteral Nutr 2006;30:487-91
46. Tytgat GN, Huibregtse K. Loperamide and ileostomy output-placebo-controled double-blind crossover study. Br Med J 1975;2:667-8
47. Tytgat GN, Huibregtse K, Dagevos J, van den Ende A. Effect of loperamide on fecal output and composition in wellestablished ileostomy and ileorectal anastomosis. Am J Dig Dis 1977;22:669-76
48. Gruy Kapral C, Little KH, Fordtran JS, et al. Conjugated bile acid replacement therapy for short-bowel syndrome. Gastroenterology 1999;116:15-21
49. Heydorn S, Jeppesen PB, Mortensen PB. Bile acid replacement therapy with cholylsarcosine for short- bowel syndrome. Scand J Gastroenterol 1999;34:818-23
50. Kapral C, Wewalka F, Praxmarer V, et al. Conjugated bile acid replacement therapy in short bowel syndrome patients with a residual colon. Z Gastroenterol 2004;42:583-9
51. Byrne TA, Morrissey TB, Nattakom TV, et al. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. JPEN J Parenter Enteral Nutr 1995;19:296-302
52. Byrne TA, Persinger RL, Young LS, et al. A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann Surg 1995;222:243-54
53. Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 2000;46:701-6
54. Scolapio JS, Camilleri M, Fleming CR, et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology 1997;113:1074-81
55. Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut 2000;47:199-205
56. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg 1997;225:88-96
57. Seguy D, Vahedi K, Kapel N, et al. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology 2003;124:293-302
58. Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg 2005;242:655-61
59. Johannsson G, Sverrisdottir YB, Ellegard L, et al. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab 2002;87:1743-9
60. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon- like peptide 2. Proc Natl Acad Sci USA 1996;93:7911-16
61. Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828-32
62. Wojdemann M, Wettergren A, Hartmann B, et al. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84:2513-17
63. Bremholm L, Hornum M, Andersen UB, et al. The effect of glucagon-like peptide- 2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept 2011;168:32-8
64. Hoyerup P, Hellstrom PM, Schmidt PT, et al. Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients. Regul Pept 2013;180:12-16
65. Cani PD, Possemiers S, Van de WT, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-103
66. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997;272:E1050-8
67. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX- 0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31.
68. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011;60:902-14.
69. OKeefe SJ, Jeppesen PB, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel syndrome intestinal failure. Clin Gastroenterol Hepatol 2013; [Epub ahead of print]
70. Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012;143:1473-81
71. Jeppesen PB, Szkudlarek J, Hoy CE, Mortensen PB. Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study. Scand J Gastroenterol 2001;36(1):48-54
72. Wales PW, Nasr A, de Silva N, Yamada J. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst Rev 2010;CD006321
73. NPS Pharmaceuticals. GATTEX (teduglutide [rDNA origin]) for injection Prescribing Information. 2012
74. Madsen KB, Askov-Hansen C, Naimi RM, et al. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebocontrolled study. Regul Pept 2013; [Epub ahead of print]
75. Kunkel D, Basseri B, Low K, et al. Efficacy of the glucagon-like peptide- 1 agonist exenatide in the treatment of short bowel syndrome. Neurogastroenterol Motil 2011;23:739-e328
76. Kissow H, Hartmann B, Holst JJ, Poulsen SS. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut 2012; [Epub ahead of print]